MAPT and Alzheimer disease: Instead, the new A/T/N framework [1] (a) requires tau positivity to formulate a diagnosis of clinical AD (AD dementia, or MCI due to AD, as opposed to Alzheimer’s pathologic change defined by biomarkers), and (b) depicts cases with positive tau and negative Aβ as belonging to a non-AD, but still to a dementing neurodegenerative disorders continuum that is relevant to the clinical aim of providing patients with accurate and timely diagnosis.